Literature DB >> 3598603

Use of resealed erythrocytes as delivery system for C-reactive protein (CRP) to generate macrophage-mediated tumoricidal activity.

S Gautam, B Barna, T Chiang, J Pettay, S Deodhar.   

Abstract

We have shown previously in several mouse tumor systems that multilamellar vesicles (MLV) are an effective delivery system for generation of macrophage-mediated tumoricidal activity by C-reactive protein (CRP). Here we show that resealed erythrocyte ghosts (red cell ghosts, RCG) can function in the same manner. CRP associated with red cell ghosts (CRP-RCG) inhibited established lung metastases of T241 fibrosarcoma in C57B1/6J mice. The degree of inhibition was comparable to that observed with CRP-MLV. In other experiments, peritoneal exudate cells, obtained from mice pretreated with CRP-RCG i.p., inhibited growth and pulmonary metastases of T241 tumor in the Winn neutralization assay. Similar results were obtained with MCA-38 colon carcinoma in the Winn assay. These studies indicate that erythrocytes deserve consideration as another delivery system for biological response modifiers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598603

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  3 in total

1.  Degradation of rat C-reactive protein by macrophages.

Authors:  A Nagpurkar; D Hunt; C Y Yang; S Mookerjea
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

2.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 3.  C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.

Authors:  Lawrence A Potempa; Ibraheem M Rajab; Margaret E Olson; Peter C Hart
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.